CORCEPT THERAPEUTICS INC 8-K

What Happened
Corcept Therapeutics (CORT) filed an 8-K reporting that on May 19, 2026 the U.S. Department of Justice filed a Notice of Election to Decline Intervention in a civil qui tam action captioned U.S. et al. ex rel. Stephen Elliott v. Corcept Therapeutics, Inc., No. 17-CV-1303 (SRC) (D.N.J.). The suit was originally filed in February 2017 by a former employee (the Relator). The DOJ’s Notice states the DOJ, the California Department of Insurance and the named Plaintiff States declined to intervene. The Relator served an amended complaint on Corcept on June 2, 2026. Corcept said it intends to vigorously defend against all of the Relator’s claims.

Key Details

• DOJ filed a Notice of Election to Decline Intervention on May 19, 2026.
• Relator (Stephen Elliott) served an amended complaint on June 2, 2026.
• In Nov 2021 the DOJ issued a records subpoena to Corcept seeking information about Korlym® sales and promotion, payments/relationships with health care professionals, and prior authorizations/reimbursement; Corcept responded in full.
• Case: U.S. et al. ex rel. Stephen Elliott v. Corcept Therapeutics, Inc., No. 17-CV-1303 (SRC) (D.N.J.).

Why It Matters
This is a legal development that creates ongoing litigation risk for Corcept; DOJ’s decision not to intervene does not dismiss the relator’s case — the private plaintiff can continue prosecution. The company has not quantified any potential financial impact and says it will vigorously defend the claims. Investors should watch future court filings and the company’s SEC reports (10-K/10-Q) for updates and any disclosed financial exposure. The 8-K also includes the company’s forward-looking statement caution about risks and uncertainties.